Teva to Commercialize Formycon’s Biosimilar Fymskina® in Germany

Formycon AG has announced a significant partnership with Teva's subsidiary, Ratiopharm, for the commercialization of its Stelara® biosimilar FYB202, branded as Fymskina®, in Germany. Under this agreement, Formycon will handle manufacturing and supply, while Ratiopharm will manage commercialization on a semi-exclusive basis.

The market launch for Fymskina® is scheduled for the third quarter of 2025. This collaboration aims to expand the market presence for Formycon's biosimilar, building on its previous agreements with Fresenius Kabi. The initiative is geared towards increasing patient access to high-quality biosimilars.

Fymskina® has already received approval from the European Commission for treating conditions such as Crohn's disease, plaque psoriasis, and psoriatic arthritis.